Physician profile
Ancy Tom
NPI 1669840203
$7,798.52
in general payments reported to CMS, 2019-2025
25 companies · $3,887 in 2025
The $3,887 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $872 · 2023: $683 · 2024: $1,952 · 2025: $3,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,411 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,411.41 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,120.24 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $943.40 | 2021-2025 | Caplyta |
| Alkermes, INC. | $684.97 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $647.61 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $640.50 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $512.44 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| Vanda Pharmaceuticals INC. | $489.40 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $487.57 | 2024-2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.81 | 2021-2025 | Relistor, Trulance |
| Neurocrine Biosciences, INC. | $325.18 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $260.17 | 2022-2025 | Auvelity |
| Lundbeck LLC | $218.49 | 2022-2025 | Rexulti |
| Almatica Pharma LLC | $206.26 | 2024-2025 | Loreev Xr, Teriparatide |
| Forte Bio-Pharma LLC | $142.08 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Takeda Pharmaceuticals U.S.A., INC. | $138.29 | 2022-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $123.44 | 2022-2023 | Qelbree |
| Protega Pharmaceutials INC | $99.66 | 2024-2025 | Roxybond |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.23 | 2021 | |
| Avanir Pharmaceuticals, INC. | $57.76 | 2021 | |
| Idorsia Pharmaceuticals US INC | $57.46 | 2022-2023 | Quviviq |
| Eisai INC. | $37.04 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $27.59 | 2024-2025 | Horizant |
| Exact Sciences Corporation | $21.52 | 2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $21.16 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ancy Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.